Ray Snyder

2.8k total citations · 1 hit paper
14 papers, 843 citations indexed

About

Ray Snyder is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Ray Snyder has authored 14 papers receiving a total of 843 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Cancer Research and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Ray Snyder's work include HER2/EGFR in Cancer Research (6 papers), Cancer Treatment and Pharmacology (6 papers) and Breast Cancer Treatment Studies (4 papers). Ray Snyder is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Cancer Treatment and Pharmacology (6 papers) and Breast Cancer Treatment Studies (4 papers). Ray Snyder collaborates with scholars based in Australia, United States and Switzerland. Ray Snyder's co-authors include Alan S. Coates, Val Gebski, G Gill, Maureen Byrne, James F. Bishop, Robert L. Woods, Martin H.N. Tattersall, P. N. Jeal, VJ Harvey and Richard D. Gelber and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Ray Snyder

14 papers receiving 811 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer

1987 419 citations Alan S. Coates, Val Gebski et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ray Snyder Australia	10	652	251	170	144	93	14	843
G Gill Australia	8	445 0.7×	135 0.5×	181 1.1×	76 0.5×	102 1.1×	14	809
Robin Stuart‐Harris Australia	17	415 0.6×	129 0.5×	162 1.0×	88 0.6×	41 0.4×	32	725
J Robert Canada	9	586 0.9×	445 1.8×	194 1.1×	79 0.5×	73 0.8×	16	955
Anna Ceribelli Italy	15	577 0.9×	132 0.5×	449 2.6×	159 1.1×	66 0.7×	35	1.0k
Joan S. McClure United States	13	499 0.8×	162 0.6×	209 1.2×	55 0.4×	148 1.6×	25	809
C. Johnston United Kingdom	6	432 0.7×	203 0.8×	136 0.8×	87 0.6×	87 0.9×	9	701
Nicole J. Look Hong Canada	18	631 1.0×	183 0.7×	289 1.7×	75 0.5×	97 1.0×	62	1.1k
Anasooya Abraham United States	15	446 0.7×	278 1.1×	233 1.4×	64 0.4×	82 0.9×	20	1.1k
Katherine Enright Canada	10	412 0.6×	216 0.9×	138 0.8×	119 0.8×	55 0.6×	36	627
Roman Shyyan United States	7	618 0.9×	167 0.7×	191 1.1×	59 0.4×	136 1.5×	8	981

Countries citing papers authored by Ray Snyder

Since Specialization

Citations

This map shows the geographic impact of Ray Snyder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ray Snyder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ray Snyder more than expected).

Fields of papers citing papers by Ray Snyder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ray Snyder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ray Snyder. The network helps show where Ray Snyder may publish in the future.

Co-authorship network of co-authors of Ray Snyder

This figure shows the co-authorship network connecting the top 25 collaborators of Ray Snyder. A scholar is included among the top collaborators of Ray Snyder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ray Snyder. Ray Snyder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Lee, Belinda, Ben Tran, Arthur Hsu, et al.. (2018). Exploring the feasibility and utility of exome‐scale tumour sequencing in a clinical setting. Internal Medicine Journal. 48(7). 786–794. 3 indexed citations

Wilcken, Nicholas, Nicholas Zdenkowski, Michelle White, et al.. (2014). Systemic treatment of HER2‐positive metastatic breast cancer: A systematic review. Asia-Pacific Journal of Clinical Oncology. 10(S4). 1–14. 17 indexed citations

Aebi, Stefan, Zijie Sun, Danielle Braun, et al.. (2011). Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Annals of Oncology. 22(9). 1981–1987. 46 indexed citations

Goel, Shom, Jacquie Chirgwin, Prudence A. Francis, et al.. (2010). Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. The Breast. 20(2). 101–110. 10 indexed citations

Green, M. D., Prudence A. Francis, Val Gebski, et al.. (2009). Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Annals of Oncology. 20(11). 1813–1817. 51 indexed citations

Coates, Alan S., J. Forbes, Jack Cuzick, et al.. (2008). Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1). Journal of Clinical Oncology. 26(15_suppl). 1516–1516. 2 indexed citations

Berclaz, Gilles, Karen N. Price, Alan S. Coates, et al.. (2004). Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Annals of Oncology. 15(6). 875–884. 202 indexed citations

Extra, J.M., F. Cognetti, Ray Snyder, et al.. (2004). Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial. European Journal of Cancer Supplements. 2(3). 125–126. 15 indexed citations

Extra, Jean-Marc, F. Cognetti, Shiu‐Wan Chan, et al.. (2003). 672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer. European Journal of Cancer Supplements. 1(5). S202–S202. 33 indexed citations

10.

Goldhirsch, Aron, Richard D. Gelber, Monica Castiglione, et al.. (1994). Present and future projects of the international breast cancer study group. Cancer. 74(S3). 1139–1149. 15 indexed citations

11.

Coates, Alan S., Val Gebski, James F. Bishop, et al.. (1987). Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer. New England Journal of Medicine. 317(24). 1490–1495. 419 indexed citations breakdown →

12.

Snyder, Ray, Bishop J, W. Ivon Burns, et al.. (1987). Phase I study of epirubicin given on a weekly schedule.. PubMed. 71(3). 273–6. 1 indexed citations

13.

Snyder, Ray, et al.. (1979). Adenocarcinoma of unknown primary site: A clinico‐pathological study. Medical and Pediatric Oncology. 6(4). 289–294. 21 indexed citations

14.

Hortobágyi, Gabriel N., Jordan U. Gutterman, Ray Snyder, Stephen P. Richman, & E. M. Hersh. (1978). Pseudomonas vaccine: A phase I evaluation for cancer research. Cancer Immunology Immunotherapy. 4(3). 201–207. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact